The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.
Providing continuing support for the SHDSL product portfolio NEWBURYPORT, Mass.–(BUSINESS WIRE)–#MaxLinear–MaxLinear, Inc., an industry leader in high-performance analog and mixed-signal integrated ...
Cloudflare's Threat Intelligence Portal provides a centralized view across the entire threat landscape. Through Cloudforce One, Cloudflare now offers its own experts to help identify and respond to ...